ClinicalTrials.gg
CompletedNCT02194491Updated Jun 28, 2016

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

A Phase 1 interventional study of [11C]AS2471907 and Positron Emission Tomography (PET) in Pharmacokinetics of ASP3662, Displacement of Radiotracer and Healthy Volunteers, sponsored by Astellas Pharma Global Development, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-28.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate a novel PET tracer ([11C]AS2471907), and to use [11C]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.

Read the detailed description

This is a two-part study where Part 1 will assess the test/retest variability of the ligand ([11C]AS2471907). Part 2 will assess the level and time-course of enzyme occupancy following ASP3662 dosing. Subjects will be confined to the clinic for up to 2 days.

02

Conditions studied

  • Pharmacokinetics of ASP3662
  • Displacement of Radiotracer
  • Healthy Volunteers

Keywords

  • [11C]AS2471907
  • ASP3662
  • Positron Emission Tomography (PET)
  • Brain enzyme occupancy
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is of non-Asian descent.
  • Subject has a (BMI) range of 18.5 to 32 kg/m2, inclusive and weighs at least 50 kg at screening.
  • Subject and his female spouse/partner who is of must be using highly effective contraception1 consisting of 2 forms of (at least one of which must be a barrier method) starting at screening and continuing throughout the study period and for 90 days after final study drug administration.
  • Subject must not donate sperm starting at screening, throughout the study period and for at least 90 days after final study drug administration.
  • Subject agrees not to participate in another study while on study treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject has a known or suspected to ASP3662, [11C]AS2471907 or intolerance of drugs with the same mechanism of action as ASP3662.
  • Subject has an allergy to topical anesthetics, such as, lidocaine (if used for catheter placement).
  • Subject has previously participated in a clinical study with ASP3662 or part 1 of the current study.
  • Subject has any of the liver enzymes ( [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT]) or total (TBIL) above the (ULN). If any liver enzyme is > 1 x ULN but ≤ 1.5 x ULN, the assessment may be repeated once during the screening period or on check-in. If the repeated assessment is above the ULN, it is exclusionary. If the initial value is > 1.5 x ULN, it cannot be repeated and is exclusionary.
  • Subject has any history of allergic conditions.
  • Subject with a history of a suicide attempt or suicidal behavior.
  • Subject has a history of smoking within the past 6 months.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal (GI), endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or , as judged by the investigator or designee.
  • Subject has/had febrile illness or symptomatic viral, bacterial (including upper respiratory infection) or fungal (non-cutaneous) infection within 1 week before clinic check-in.
  • Subject has any clinically significant abnormality following the investigator's review of the physical examination, (ECG) and protocol-defined clinical laboratory tests at screening or clinic check-in.
  • Subject has a mean pulse \< 40 or > 90 beats per minute; mean systolic blood pressure > 140 mmHg or mean diastolic blood pressure > 90 mmHg (measurements taken in triplicate after subject has been resting in supine position for 10 minutes) at screening. If the mean pulse or mean systolic blood pressure (SBP) or mean diastolic blood pressure (DBP) is out of the range specified above, 1 additional triplicate measurement may be taken at screening.
  • Subject has a mean interval of > 430 msec at screening or check-in. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken at screening. If this triplicate also gives an abnormal result, the subject should be excluded.
  • Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease or a family history of Long QT Syndrome.
  • Subject has use of any prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's wort) in the 2 weeks before study drug administration, except for occasional use of acetaminophen (up to 2 g/day).
  • Subject has history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical or substance abuse within the past 2 years prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject tests positive at screening or clinic admission for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates).
  • Subject has any use of drugs of abuse within 3 months before screening or check-in.
  • Subject has use of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to check-in.
  • Subject has consumed any caffeine-containing product within 24 hours prior to admission or grapefruit or star fruit within 7 days prior to admission.
  • Subject has any significant blood loss, donated equal to 1 unit (450 mL) or more of blood or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days before check-in.
  • Subject has a positive serology test for surface antigen, anti-hepatitis A virus (Immunoglobulin M), anti- virus or anti- (HIV) Type 1 or Type 2 at screening.
  • Subject has participated in any interventional clinical study or has been treated with any drugs within 30 days or 5 half-lives, whichever is longer, before the initiation of screening.
  • Subject is an employee of the Astellas Group or vendors involved in the study.
  • Additionally, a subject who meets the following imaging exclusion criteria will not be included in this study:

    • Subject who suffers from claustrophobia.
    • Subject who has received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study.
    • Participation in other research studies involving ionizing radiation within 1 year of the PET scans that would cause the subject to exceed the US Nuclear Regulatory Commission yearly dose limits for healthy subjects, i.e., an effective dose of 5 Roentgen equivalent man (rem) received per year.
    • Subject with history of IV drug use which would prevent venous access for PET tracer injection.
    • Severe motor problems that prevent the subject from lying still for PET imaging.
    • Subject who has chronic pain for any reason (e.g., as the result of rheumatoid arthritis).
    • Subject who has an MRI scan deemed to be structurally abnormal by the investigator and thus precluding proper identification of the regions of interest (ROIs) (e.g., cortical atrophy). The MRI scan for an individual subject may be omitted if the required anatomical MRI scan for this subject is on file and was performed within approximately 6 months prior to dosing, as part of participation in an approved Yale Protocol.
    • Subjects who has current, past or anticipated exposure to radiation in the work place.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    [11C]AS2471907 administration (Part 1)

    Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.

    Other: [11C]AS2471907 · Radiation: Positron Emission Tomography (PET)

  • Experimental
    ASP3662 administration (Part 2)

    The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.

    Radiation: Positron Emission Tomography (PET) · Drug: ASP3662

Interventions

  • Other[11C]AS2471907

    intravenous radiotracer

    Also known as: Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.

  • RadiationPositron Emission Tomography (PET)

    Imaging scanning procedure

  • oral

06

What researchers measure

Primary outcomes

  1. Positron Emission Tomography measure: volume of distribution

    Time frame: Day 1 and 2 (Part 1 and Part 2)

  2. Positron Emission Tomography measure: brain time-activity curves

    Time frame: Day 1 and 2 (Part 1 and Part 2)

  3. Positron Emission Tomography measure: enzyme occupancy

    Time frame: Day 1 and 2 (Part 1 and Part 2)

  4. Positron Emission Tomography measure: binding potentials

    Time frame: Day 1 and 2 (Part 1 and Part 2)

  5. Pharmacokinetic parameter of ASP3662 and its metabolite (AS2570469): AUClast (Part 2 only)

    Area under the plasma concentration - time curve from time zero to time of last measurable concentration (AUClast)

    Time frame: Day 1 and 2

  6. Pharmacokinetic parameter of ASP3662 and its metabolite (AS2570469): Cmax (Part 2 only)

    Maximum concentration (Cmax)

    Time frame: Day 1 and 2

  7. Pharmacokinetic parameter of ASP3662 and its metabolite (AS2570469): tmax (Part 2 only)

    Time to attain Cmax (tmax)

    Time frame: Day 1 and 2

  8. Safety as assessed by laboratory tests, 12-lead electrocardiograms, vital signs, adverse events, physical exams, neurological exams and Columbia Suicide Severity Rating Scale

    Time frame: up to 9 days (Part 1 and Part 2)

07

Study locations

1 site
  • Site US10001
    New Haven, Connecticut 06520-8-48, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2014
First posted
Jul 18, 2014
Start
Apr 2014
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Jun 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02194491
Collaborators
Yale University
Responsible party
Sponsor
First posted
Jul 18, 2014
Start date
Apr 2014
Primary completion
May 2016
Completion
May 2016
Last update
Jun 28, 2016

Study contacts

Senior Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ASP3662

Start the discussion